# EDGAR Filing Document

**Accession Number:** 0001840574
**File Stem:** 0001193125-25-162670
**Filing Date:** 2025-7
**Character Count:** 8644
**Document Hash:** 5a08bb13239ea17e13becf37612ccbf2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-162670.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001193125-25-162670

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250722

**DATE AS OF CHANGE**: 20250722

**GROUP MEMBERS**: RIDGEWAY ACQUISITION CORP

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verve Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824800132
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92605
- **FILM NUMBER:** 251141039

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (978) 501-3026

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ELI LILLY & Co
- **CENTRAL INDEX KEY:** 0000059478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 350470950
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** LILLY CORPORATE CTR
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285
- **BUSINESS PHONE:** 3172762000

**MAIL ADDRESS:**
- **STREET 1:** LILLY CORPORATE CENTER
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LILLY ELI & CO
- **DATE OF NAME CHANGE:** 19941024

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE TO** 

**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)** 

**of the Securities Exchange Act of 1934** 

**(Amendment No. 2)** 

## VERVE THERAPEUTICS, INC.
**(Name of Subject Company (issuer))** 

## RIDGEWAY ACQUISITION CORPORATION
**(Offeror)** 

**an indirect wholly-owned subsidiary of** 

## ELI LILLY AND COMPANY
**(Parent of Offeror)** 

**(Names of Filing Persons (identifying status as offeror, issuer or other person))** 

**Common stock, $0.001 par value per share** 

**(Title of Class of Securities)** 

**92539P101** 

**(CUSIP Number of Class of Securities)** 

**Anat Hakim** 

**Executive Vice President, General Counsel and Secretary** 

**Eli Lilly and Company** 

**Lilly Corporate Center** 

**Indianapolis, Indiana 46285** 

**Telephone: (317) 276-2000** 

**(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)** 

***Copy to:***

**Sophia Hudson, P.C.** 

**Sharon Freiman, P.C.** 

**Kirkland & Ellis LLP** 

**601 Lexington Avenue** 

**New York, New York 10022** 

**Telephone: (212) 446-4800** 

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Third-party tender offer subject to Rule 14d-1.

☐ Issuer tender offer subject to Rule 13e-4.

☐ Going-private transaction subject to Rule 13e-3.

☐ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Amendment No. 2 to the Tender Offer Statement on Schedule TO (this "Amendment") amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on June 25, 2025 (as it may be further amended and supplemented from time to time, the "Schedule TO") and relates to the offer by Ridgeway Acquisition Corporation, a Delaware corporation ("Purchaser") and an indirect wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation ("Lilly"), to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Verve Therapeutics, Inc., a Delaware corporation ("Verve"), in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, *plus* (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone, all in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement to be entered into by and among Purchaser, Lilly, Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 25, 2025 (the "Offer to Purchase"), and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, collectively constitute the "Offer"), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

The Offer will expire at one minute past 11:59 p.m., Eastern Time, on July 23, 2025, unless the Offer is extended or earlier terminated (such time or such subsequent time to which the expiration of the Offer is extended, the "Expiration Time"). In the case of an extension of the Expiration Time, a public announcement of such extension will be made no later than 9:00 a.m., Eastern Time, on the business day after the previously scheduled Expiration Time. The terms and conditions relating to the Offer, including the procedures regarding the extension of the Expiration Time, are described in Section 1 — "Terms of the Offer" of the Offer to Purchase.

Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the respective meanings ascribed to them in the Schedule TO.

***Items 1 through 9 and Item 11.***

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented by adding the following new paragraph at the end of Section 15 — "*Conditions of the Offer*" of the Offer to Purchase:

"The Antitrust Condition has been satisfied by the early termination of the waiting period under the HSR Act, effective July 22, 2025 at 1:30 p.m., Eastern Time."

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented by deleting the second paragraph under the subheading "*Antitrust Compliance*" in Section 16 — "Certain Legal Matters; Regulatory Approvals" of the Offer to Purchase and replacing it with the following paragraph:

"Lilly and Verve filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the FTC and the Antitrust Division on June 25, 2025 initiating a 30-day waiting period. On July 22, 2025 at 1:30 p.m., Eastern Time, the FTC granted a request for the early termination of the waiting period under the HSR Act. Accordingly, the Antitrust Condition has been satisfied. The Offer continues to be subject to the remaining conditions set forth in this Offer to Purchase. See Section 15 — "Conditions of the Offer.""

------

**SIGNATURES** 

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Date: July 22, 2025 | **RIDGEWAY ACQUISITION CORPORATION** | **RIDGEWAY ACQUISITION CORPORATION** |
|  | /s/ Jonathan R. Haug | /s/ Jonathan R. Haug |
|  | Name: | Jonathan R. Haug |
|  | Title: | President |
|  | **ELI LILLY AND COMPANY** | **ELI LILLY AND COMPANY** |
|  | /s/ Jonathan Groff | /s/ Jonathan Groff |
|  | Name: | Jonathan Groff |
|  | Title: | Associate Vice President and Assistant General Counsel |

---